First published data on our development program, MosaiQ™

Posted

At the 2013 Annual Meeting for AABB, Quotient presented two posters of the first published results from our development program, MosaiQ.  The first poster, which had been selected by AABB as a "Top Poster" and entitled "Evaluation of a Novel Serology-Based Platform for Irregular Blood Group Antibody Identification (MosaiQ)", presented data from a 1,000 sample study demonstrating the ability to identify irregular blood group antibodies using MosaiQ. 

The second poster entitled "ABO and Rh Antigen Typing of Red Blood Cells Using a Novel Serology Based Multiplexed Protein Microarray Platform (MosaiQ)" presented data from a study using 1,022 samples demonstrated the feasibility of the MosaiQ platform as an antigen typing platform.

In both studies results were compared and correlated to column agglutination technology.

There will be several more scientific presentations on MosaiQ in the next few months.

Quotient Puts the CE in CompEtency

Posted

Quotient has launched an e-learning website powered by beLearning™  www.bcw.edu/qcases  where the customer can access Continuing Education case studies, specifically designed to synchronize wi...

Read More »

Complying with CAP TRM.31450

Posted

Both CMS (42 CFR 493.1281) and the College of American Pathologists (TRM.31450 & COM.04250) require laboratories that use more than one method of testing a given analyte to have a system in pla...

Read More »

Get Answers Here